Israeli medical company Inmode (INMD.US) is trading down more than 10% today, after it lowered its full-year guidance for 2023, citing stronger-than-expected pressure from macroeconomic headwinds.
- As a result, the company sees lower interest in services in its proprietary medical platform. Inmode now expects $2.47 to $2.5 in annual earnings per share, versus $2.53 to $2.57 previously. Revenues are expected to be in the range of $485 to $495 million vs. $500 to $510 million estimated previously.
- The company maintains very high net margins, which stood at 36% in Q3, with close to zero debt. Since October 7, shares have plunged due to uncertainty surrounding the conflict in Israel and a broader escalation in the Middle East. The company itself reported that its supply chains, workers and production are safe and the local Israeli market accounts for less than 1% of its total sales.
![]()
Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
